Edition:
India

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

78.31USD
23 Apr 2018
Change (% chg)

$-1.68 (-2.10%)
Prev Close
$79.99
Open
$80.61
Day's High
$80.61
Day's Low
$76.54
Volume
682,900
Avg. Vol
474,770
52-wk High
$84.35
52-wk Low
$28.82

Chart for

About

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne... (more)

Overall

Beta: 1.28
Market Cap(Mil.): $3,262.29
Shares Outstanding(Mil.): 64.33
Dividend: --
Yield (%): --

Financials

BRIEF-Sarepta Therapeutics Announces Plan To Submit A New Drug Application For Accelerated Approval Of Golodirsen

* SAREPTA THERAPEUTICS ANNOUNCES PLAN TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR ACCELERATED APPROVAL OF GOLODIRSEN (SRP-4053) IN PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY (DMD) AMENABLE TO SKIPPING EXON 53

12 Mar 2018

BRIEF-Sarepta Therapeutics Reports Q4 Non-GAAP Loss Per Share $0.28

* SAREPTA THERAPEUTICS ANNOUNCES FOURTH QUARTER 2017 AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE DEVELOPMENTS

02 Mar 2018

BRIEF-Capital Ventures International Reports 5.4 Pct Passive Stake In Sarepta Therapeutics

* CAPITAL VENTURES INTERNATIONAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN SAREPTA THERAPEUTICS INC AS OF DECEMBER 11, 2017 - SEC FILING Source text: (http://bit.ly/2kzjwV3) Further company coverage:

21 Dec 2017

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

10 Nov 2017

UPDATE 1-Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

10 Nov 2017

Health insurer Anthem eases restrictions on Sarepta's Duchenne treatment

NEW YORK, Nov 9 Health insurer Anthem Inc has eased access to Sarepta Therapeutics' treatment for Duchenne muscular dystrophy, and on Thursday changed its reimbursement policy on its website to "medically necessary."

09 Nov 2017

BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes

* Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024

08 Nov 2017

BRIEF-Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051

* Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051

07 Nov 2017

BRIEF-Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program

* Sarepta Therapeutics and Nationwide Children’s Hospital announce FDA clearance of IND for micro-dystrophin gene therapy program for the treatment of duchenne muscular dystrophy Source text for Eikon: Further company coverage:

06 Nov 2017

BRIEF-Sarepta Therapeutics signs exclusive global collaboration with Duke University

* Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD)

31 Oct 2017

Earnings vs. Estimates